Literature DB >> 17008066

Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.

José R Hernández1, Carmen Velasco, Luisa Romero, Luís Martínez-Martínez, Alvaro Pascual.   

Abstract

The in vitro activity of ertapenem was tested against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain. Ertapenem activity was similar to that of imipenem and meropenem and better than that of the other antimicrobials tested. No differences in activity were observed regarding the origin of the isolates or type of ESBL produced.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17008066     DOI： 10.1016/j.ijantimicag.2006.08.014

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


  3 in total

1.  Fatal endocarditis due to extended spectrum betalactamase producing Klebsiella terrigena in a liver transplant recipient.

Authors:  Hannes Goegele; Elfriede Ruttmann; Jaime Aranda-Michel; Reinhold Kafka; Ingrid Stelzmueller; Hans Hausdorfer; Robert Sawyer; Raimund Margreiter; Hugo Bonatti
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

2.  In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli.

Authors:  M Tärnberg; A Ostholm-Balkhed; H-J Monstein; A Hällgren; H Hanberger; L E Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-06       Impact factor: 3.267

3.  Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.

Authors:  Marie-Laure Joly-Guillou; Marie Kempf; Jean-Didier Cavallo; Monique Chomarat; Luc Dubreuil; Jeanne Maugein; Claudette Muller-Serieys; Micheline Roussel-Delvallez
Journal:  BMC Infect Dis       Date:  2010-03-18       Impact factor: 3.090
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.